Multi-Marker Protein Panel Detects Ovarian Cancer Up To Two Years Earlier

Researchers at Queens University Belfast have published findings where a multi-marker panel of 4 proteins (CA125, phosphatidylcholine-sterol aceltransferase, vitamin K-dependent protein Z, and CRP) has the potential to diagnose epithelial ovarian cancer (EOC) one to two years earlier than current methods.

The SpotProfiler is a prime candidate to translate this type of research finding into an easily accessible medical tool for physicians with its multi-marker protein microarray approach.

Categories: diagnostics

Published on by Winnie So. Source.

How a long-known biomarker backs BioNTech's antibody for pancreatic cancer

CA19-9 is a sugar molecule present on many proteins. It is often elevated in patients with pancreatitis and pancreatic cancer; hence, it has been used for more than 30 years to assess disease burden. Recently, scientists at Cold Spring Harbor Laboratory (CSHL) have found that CA19-9 may actually promote the development of these pancreatic diseases and that blocking CA19-9 could serve as a therapeutic strategy. An antibody drug targeting CA19-9, MVT-5873, is in clinical testing for pancreatic cancer and was acquired by German biotech BioNTech.


Published on by Winnie So. Source.

Bio-Techne nets FDA breakthrough ticket in prostate cancer liquid biopsy

Bio-Techne’s urine test, ExoDx Prostate IntelliScore test, tracks down the exosomes and genomic markers released from prostate cancer cells. It is the first liquid biopsy to receive breakthrough status from the FDA for targeting exosomes. The aim of the test is to rule out unnecessary tissue biopsies following the results of a prostate-specific antigen (PSA) test, which can give false positive results.

Categories: regulatory

Published on by Winnie So. Source.

Tabletop blood count developer Sight raises $27.8M in series C round

Sight Diagnostics received the CE Mark last year for its OLO system, which uses digital microscopy to visually analyze cell types by size, shape, count and morphology, from a few drops of blood during a single office visit. The technology has been used to screen over 600,000 samples for malaria infections and will now be adding complete blood count testing to its system. Sight Diagnostics has raised US$27.8 million to continue its global commercial expansion, fund regulatory efforts and support its research and development.

Categories: diagnostics, finance

Published on by Winnie So. Source.